BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang H, Chen X, Li K, Cheaito H, Yang Q, Wu G, Liu J, Dou QP. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Semin Cancer Biol 2021;68:105-22. [PMID: 31883910 DOI: 10.1016/j.semcancer.2019.12.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Z, Liu X, Zhao L, Zhou Y, Shi J, Chen W, Li J. A review on the treatment of multiple myeloma with small molecular agents in the past five years. Eur J Med Chem 2022;229:114053. [PMID: 34974338 DOI: 10.1016/j.ejmech.2021.114053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Jayaweera SPE, Wanigasinghe Kanakanamge SP, Rajalingam D, Silva GN. Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma. Front Oncol 2021;11:740796. [PMID: 34858819 DOI: 10.3389/fonc.2021.740796] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
3 Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, Dou QP, Franz KJ, Gohil VM, Gupta S, Kaler SG, Lutsenko S, Mittal V, Petris MJ, Polishchuk R, Ralle M, Schilsky ML, Tonks NK, Vahdat LT, Van Aelst L, Xi D, Yuan P, Brady DC, Chang CJ. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer 2021. [PMID: 34764459 DOI: 10.1038/s41568-021-00417-2] [Cited by in F6Publishing: 68] [Reference Citation Analysis]
4 El Yaagoubi OM, Oularbi L, Bouyahya A, Samaki H, El Antri S, Aboudkhil S. The role of the ubiquitin-proteasome pathway in skin cancer development: 26S proteasome-activated NF-κB signal transduction. Cancer Biol Ther 2021;:1-14. [PMID: 34583610 DOI: 10.1080/15384047.2021.1978785] [Reference Citation Analysis]
5 Wang Z, Li Z, Xu H, Liao Y, Sun C, Chen Y, Sheng M, Lan Q, Wang Z. PSMD12 promotes glioma progression by upregulating the expression of Nrf2. Ann Transl Med 2021;9:700. [PMID: 33987398 DOI: 10.21037/atm-21-1481] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
6 Fhu CW, Ali A. Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention. Cancers (Basel) 2021;13:1513. [PMID: 33805973 DOI: 10.3390/cancers13071513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
7 Gurusingha Arachchige HS, Herath Mudiyanselage PDH, VanHecke GC, Patel K, Cheaito HA, Dou QP, Ahn YH. Synthesis and evaluation of tiaprofenic acid-derived UCHL5 deubiquitinase inhibitors. Bioorg Med Chem 2021;30:115931. [PMID: 33341501 DOI: 10.1016/j.bmc.2020.115931] [Reference Citation Analysis]
8 Jiang J, Sun Y, Xu J, Xu T, Xu Z, Liu P. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma. Cancer Med 2020;9:7244-52. [PMID: 32780537 DOI: 10.1002/cam4.3347] [Cited by in F6Publishing: 5] [Reference Citation Analysis]